Immunotherapy in Melanoma | Specialty

Vaccine Strategy for Biomarker in NSCLC Reaches Phase III Study

January 27th 2016

An emerging vaccine strategy, of TG4010 immunotherapy and first-line chemotherapy, that could target a potential new biomarker in patients with advanced non-small cell lung cancer (NSCLC) has successfully reached a phase III clinical trial, researchers noted.

FDA Expands Nivolumab's Frontline Melanoma Approval to Include BRAF-Mutant Patients

January 23rd 2016

The FDA has expanded the frontline melanoma indications for nivolumab as a single agent and in combination with ipilimumab to include patients with BRAF mutations.

Experts Grapple With Nuances of Navigating New Frontier in Melanoma

January 13th 2016

Questions remain in terms of how to optimally sequence and/or combine both targeted agents and immunotherapies in melanoma.

Atezolizumab/Vemurafenib Combo Shows Clinical Activity in BRAF+ Melanoma

January 12th 2016

The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.

Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell Therapy

January 8th 2016

Steven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.

Jason Luke on Significance of Biomarker Development for Immunotherapy in Melanoma

January 7th 2016

Jason J. Luke, MD, discusses potential new methods for determining prognostic markers in melanoma and the challenges of balancing toxicity with efficacy in designing combination regimens.

Nivolumab Continues to Improve Outcomes in Advanced Melanoma

January 6th 2016

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

Dr. Luke on the Future of Combination Therapy in Melanoma

January 5th 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Expert Discusses Molecular Testing and BRAF/ MEK Inhibition in Melanoma

December 29th 2015

Keith T. Flaherty, MD, discusses molecular testing issues and the use of combined BRAF/ MEK inhibition in patients with advanced/metastatic melanoma.

PD-1 Success Fuels Interest in Many Immune System Targets

December 28th 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28th 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Pembrolizumab Indication Expanded, EC Approves T-VEC, and More

December 26th 2015

T-VEC Approved in Europe for Unresectable Metastatic Melanoma

December 18th 2015

The European Commission has approved talimogene laherparepvec as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera.

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

December 18th 2015

The FDA has expanded the approval for single-agent pembrolizumab to include the frontline treatment of patients with advanced melanoma regardless of BRAF status.

Binimetinib Improves PFS in NRAS-Mutant Melanoma

December 16th 2015

The MEK inhibitor binimetinib has demonstrated an improvement in progression-free survival compared with dacarbazine in patients with advanced NRAS-mutant melanoma.

Future Advances in Melanoma Treatment

December 16th 2015

Hot Versus Cold Tumors: Predictive Markers in Melanoma

December 16th 2015

Duration of Dual BRAF-MEK Inhibition in Melanoma

December 16th 2015

Sequencing Dual BRAF-MEK Inhibition and Immunotherapy

December 16th 2015

Treatment of BRAF-Mutant Metastatic Melanoma

December 16th 2015